DK3677271T3 - Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider - Google Patents

Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider Download PDF

Info

Publication number
DK3677271T3
DK3677271T3 DK19212541.7T DK19212541T DK3677271T3 DK 3677271 T3 DK3677271 T3 DK 3677271T3 DK 19212541 T DK19212541 T DK 19212541T DK 3677271 T3 DK3677271 T3 DK 3677271T3
Authority
DK
Denmark
Prior art keywords
supernatans
microvesicles
isolation
purification
procedure
Prior art date
Application number
DK19212541.7T
Other languages
English (en)
Inventor
Evangelos V Badiavas
Arsalan Q Shabbir
Stephen C Davis
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Application granted granted Critical
Publication of DK3677271T3 publication Critical patent/DK3677271T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/983—Blood, e.g. plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
DK19212541.7T 2013-03-13 2014-03-12 Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider DK3677271T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778591P 2013-03-13 2013-03-13
EP14774189.6A EP2972193B1 (en) 2013-03-13 2014-03-12 Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids

Publications (1)

Publication Number Publication Date
DK3677271T3 true DK3677271T3 (da) 2023-05-22

Family

ID=51625222

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14774189.6T DK2972193T3 (da) 2013-03-13 2014-03-12 Fremgangsmåde til isolation og oprensning af mikrovesikler fra cellekultursupernatanter og biologiske fluider
DK19212541.7T DK3677271T3 (da) 2013-03-13 2014-03-12 Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14774189.6T DK2972193T3 (da) 2013-03-13 2014-03-12 Fremgangsmåde til isolation og oprensning af mikrovesikler fra cellekultursupernatanter og biologiske fluider

Country Status (13)

Country Link
US (4) US10500231B2 (da)
EP (3) EP2972193B1 (da)
JP (3) JP6562897B2 (da)
CN (2) CN105209881B (da)
AU (4) AU2014244618A1 (da)
CA (1) CA2906502A1 (da)
DK (2) DK2972193T3 (da)
ES (2) ES2778098T3 (da)
FI (1) FI3677271T3 (da)
HU (2) HUE062348T2 (da)
PL (2) PL3677271T3 (da)
PT (2) PT3677271T (da)
WO (1) WO2014159662A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
AU2014244618A1 (en) 2013-03-13 2015-10-08 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US11160904B2 (en) 2017-05-09 2021-11-02 Vivex Biologies Group, Inc. Biological composition in a protectant shroud and methods
US20180325830A1 (en) 2017-05-09 2018-11-15 Vivex Biomedical, Inc. Coated biological composition
US9687511B2 (en) * 2015-03-06 2017-06-27 Vivex Biomedical, Inc. Acellular biologic composition and method of manufacture
WO2016145330A1 (en) * 2015-03-11 2016-09-15 Atta Behfar Exosome delivery technology
WO2016149358A1 (en) * 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
HRP20230865T1 (hr) * 2015-07-31 2023-11-10 Exotropin, Llc Kompozicije egzosoma i postupci za njihovu pripremu i primjenu za reguliranje i kondicioniranje kože i kose
KR102418785B1 (ko) 2015-09-25 2022-07-08 (주)프로스테믹스 식물 착즙물 유래 세포 외 소포체를 포함하는 피부 개선 및 탈모 방지용 조성물
KR102475127B1 (ko) * 2015-09-30 2022-12-07 (주)아모레퍼시픽 인삼 유래의 엑소좀 유사 베지클을 포함하는 탈모 방지 또는 육모 촉진용 조성물
WO2017117585A1 (en) * 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
JP2019505590A (ja) * 2016-01-19 2019-02-28 ジェイ． サイレン、マッティ 癌の予防、処置および／または緩和における使用のための方法および組成物
KR102475129B1 (ko) * 2016-03-22 2022-12-07 (주)아모레퍼시픽 인삼 유래의 엑소좀 유사 베지클을 유효성분으로 포함하는 항노화용 조성물
WO2018039100A2 (en) * 2016-08-23 2018-03-01 Albert Einstein College Of Medicine, Inc. Stem cell-produced microvesicles for treating tendon pathologies
WO2018130554A1 (en) * 2017-01-11 2018-07-19 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
JP2020528766A (ja) * 2017-07-26 2020-10-01 ロゼッタ エクソソーム 陽イオンを利用した細胞外小胞体の分離方法
ES2968625T3 (es) * 2017-07-27 2024-05-13 Univ Cornell Un método para la fijación y retención de vesículas extracelulares, vesículas extracelulares fijadas y un método para diagnosticar una enfermedad
CN111182890A (zh) * 2017-09-22 2020-05-19 迈阿密大学 用于治疗大疱性表皮松解症的方法和组合物
US11471559B2 (en) 2017-11-20 2022-10-18 Vivex Biologics Group, Inc. Bioenergetic bone
US11660271B2 (en) 2018-01-29 2023-05-30 Forever Labs, Inc. System and method for isolating extracellular vesicles
CN108414334A (zh) * 2018-02-23 2018-08-17 中山大学附属第医院 一种从精液中分离提纯外泌体的方法
US11752175B2 (en) 2018-09-21 2023-09-12 Cornell University Compositions and methods for glaucoma
AU2020228303B2 (en) * 2019-02-28 2025-09-18 Merakris Therapeutics Llc Amniotic fluid-derived extracellular vesicles and uses thereof for wound healing
IT201900024580A1 (it) * 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN113384597A (zh) * 2020-03-13 2021-09-14 西比曼生物科技（上海）有限公司 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
CN111893093A (zh) * 2020-08-03 2020-11-06 沈阳三禾生物科技有限公司 一种脐带间充质干细胞来源的超微因子的制备方法
AU2021327376A1 (en) 2020-08-21 2023-04-20 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
WO2022080461A1 (ja) * 2020-10-16 2022-04-21 富士フイルム和光純薬株式会社 細胞外小胞の産生用培地、培地キット、添加剤及び細胞外小胞の産生方法
CN114081900B (zh) * 2021-02-24 2024-11-22 济宁医学院附属医院 间充质干细胞来源的纳米微囊泡在制备治疗子痫前期的药物中的应用
CN115212230B (zh) * 2021-04-21 2024-12-27 时比曼生物科技(上海)有限公司 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
EP4511045A1 (en) 2022-04-19 2025-02-26 University of Miami Compositions comprising microvesicles for use in the prevention and treatment of graft versus host disease
KR20240028586A (ko) * 2022-08-24 2024-03-05 (주) 테라베스트 인간 세포 유래 미세소포체 및 히알루론산 또는 콜라겐을 포함하는 조성물 및 이의 용도
CN116898781B (zh) * 2023-02-07 2025-08-15 中国中医科学院中医基础理论研究所 大麦苗外泌体在制备具有抗衰老修护作用的产品中的应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
KR20030088022A (ko) * 2000-11-30 2003-11-15 스템론 인크. 단리된 동종접합 간세포, 그로부터 유래된 분화 세포 및이들을 제조 및 사용하기 위한 물질 및 방법
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
WO2005121369A2 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
WO2006007529A2 (en) 2004-07-01 2006-01-19 University Of Pittsburgh Of The Commonwealth System For Higher Education Immunosuppressive exosomes
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
ES2880460T3 (es) 2006-03-09 2021-11-24 Aethlon Medical Inc Eliminación extracorpórea de partículas microvesiculares
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
ES2425387T3 (es) 2006-07-13 2013-10-15 The Ohio State University Research Foundation Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
AU2008226974B2 (en) 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
GB2459228B (en) 2007-07-25 2012-06-20 Univ Louisville Res Found Exosome-associated microrna as a diagnostic marker
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
JP5719171B2 (ja) * 2007-10-15 2015-05-13 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 内皮細胞移植、特に膵島移植による糖尿病の処置におけるアジュバント活性を有する医薬を調製するための微小胞（ｍｖ）の使用、および関連方法
CN101854941B (zh) * 2007-10-29 2013-03-27 弗雷森纽斯医疗护理德国有限责任公司 衍生自干细胞的微泡(MVs)用于制备用于受损或损伤组织或器官的内皮/上皮再生的药物的用途、以及相关体外和体内方法
NZ586497A (en) 2008-01-04 2012-07-27 Lydac Neuroscience Ltd Microvesicles
US20120058492A1 (en) 2008-01-25 2012-03-08 Hansabiomed Ou Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
US8617806B2 (en) 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
AU2009212543B2 (en) * 2008-02-01 2015-07-09 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
PT2254586E (pt) * 2008-02-22 2015-05-18 Agency Science Tech & Res Partículas de células estaminais mesenquimais
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
CN102065870B (zh) * 2008-04-16 2014-11-19 比奥根艾迪克Ma公司 使用聚亚烷基二醇和过渡金属分离生物大分子的方法
US10545149B2 (en) 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
AU2009308152B2 (en) 2008-10-21 2015-05-21 The General Hospital Corporation Cell transplantation
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
PT2419144T (pt) 2009-04-17 2019-09-16 Univ Oxford Innovation Ltd Composição para a administração de material genético
BRPI0900815A2 (pt) 2009-04-23 2010-12-28 Sociedade Benef Israelita Bras Hospital Albert Einstein método para isolamento de exossomos a partir de soluções biológicas utilizando nanopartìculas de óxido de ferro
AU2010268367B2 (en) 2009-07-02 2016-10-20 Ith Immune Therapy Holdings Ab Exosome based treatment of cancer
DK2454588T3 (da) * 2009-07-16 2015-09-28 Gen Hospital Corp Nukleinsyreanalyse
DK2521918T3 (da) 2010-01-08 2015-06-29 Cavadis B V Bestemmelse af exosomale biomarkører til forudsigelse af cardiovaskulære hændelser
US20120315324A1 (en) 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
US9066971B2 (en) 2010-07-01 2015-06-30 Postech Academy-Industry Foundation Method for treating and diagnosing cancer by using cell-derived microvesicles
EP2603592A2 (en) 2010-08-13 2013-06-19 The University Court of the University of Glasgow Therapeutic uses of microvesicles and related micrornas
US20120053976A1 (en) 2010-08-31 2012-03-01 Xerox Corporation System and method for determining whether service costs can be reduced
US20120093885A1 (en) * 2010-10-18 2012-04-19 Northwestern University Therapeutic vesicles
JP5911874B2 (ja) * 2010-10-18 2016-04-27 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 発毛を促進又は増強するためのエキソソームの使用
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
WO2012126531A1 (en) 2011-03-24 2012-09-27 Cavadis B.V. Method for diagnosing acute coronary syndrome (acs)
WO2012110253A2 (en) 2011-02-18 2012-08-23 Cavadis B.V. Exosomal biomarkers for cardiovascular events
WO2012110099A1 (en) 2011-02-18 2012-08-23 Cavadis B.V. Determination of exosomal biomarkers for predicting cardiovascular events
US9816998B2 (en) 2011-04-01 2017-11-14 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
EP3210662A1 (en) 2011-06-08 2017-08-30 Agency For Science, Technology And Research Purification of biological products by constrained cohydration chromatography
WO2013014669A1 (en) 2011-07-24 2013-01-31 Carmel-Haifa University Economic Corp. Lactoferrin fragments and use thereof
ITRM20110403A1 (it) * 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
US20150018227A1 (en) 2011-08-05 2015-01-15 University Of Louisville Research Foundation, Inc. Microrna biomarkers
EP2604288A1 (en) 2011-12-16 2013-06-19 Biocant - Associação De Transferência De Tecnologia Nanoparticles and uses thereof
WO2013110253A1 (de) 2011-12-23 2013-08-01 Appbyyou Gmbh Verfahren zum aufbau einer verschlüsselten verbindung zwischen zwei kommunikationsgeräten nach vorherigem schlüsselaustausch über eine kurzstreckenverbindung
US20130273544A1 (en) 2012-04-17 2013-10-17 Life Technologies Corporation Methods and compositions for exosome isolation
WO2013188832A1 (en) * 2012-06-14 2013-12-19 System Biosciences, Llc Methods for microvesicle isolation and selective removal
US9005888B2 (en) 2012-06-14 2015-04-14 System Biosciences, Llc Methods for microvesicle isolation and selective removal
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
EP3415627A1 (en) 2012-11-13 2018-12-19 Codiak BioSciences, Inc. Delivery of therapeutic agent
AU2014244618A1 (en) 2013-03-13 2015-10-08 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
WO2016043654A1 (en) 2014-09-15 2016-03-24 Agency For Science, Technology And Research Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb) with exosomes
US20160220613A1 (en) 2013-09-16 2016-08-04 Agency For Science, Technology And Research Method
WO2015138878A1 (en) 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
WO2016172598A1 (en) 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
EP3302501B1 (en) 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
WO2017123022A1 (ko) 2016-01-12 2017-07-20 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
US11918687B2 (en) 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
CN111182890A (zh) 2017-09-22 2020-05-19 迈阿密大学 用于治疗大疱性表皮松解症的方法和组合物
AU2021327376A1 (en) 2020-08-21 2023-04-20 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells

Also Published As

Publication number Publication date
AU2018211351A1 (en) 2018-08-23
JP6562897B2 (ja) 2019-08-21
US11730768B2 (en) 2023-08-22
CA2906502A1 (en) 2014-10-02
JP7405389B2 (ja) 2023-12-26
HUE062348T2 (hu) 2023-10-28
PL3677271T3 (pl) 2023-08-21
HUE049003T2 (hu) 2020-09-28
US20260091064A1 (en) 2026-04-02
EP2972193B1 (en) 2019-12-18
EP3677271A1 (en) 2020-07-08
EP3677271B1 (en) 2023-04-19
US10500231B2 (en) 2019-12-10
JP2016518109A (ja) 2016-06-23
EP4218774A1 (en) 2023-08-02
FI3677271T3 (fi) 2023-06-06
US12453745B2 (en) 2025-10-28
CN112795533A (zh) 2021-05-14
ES2778098T3 (es) 2020-08-07
AU2020223723A1 (en) 2020-09-10
ES2949637T3 (es) 2023-10-02
PL2972193T3 (pl) 2020-08-24
WO2014159662A1 (en) 2014-10-02
AU2014244618A1 (en) 2015-10-08
EP2972193A4 (en) 2016-09-07
JP2019195331A (ja) 2019-11-14
AU2018211351B2 (en) 2020-05-28
CN105209881A (zh) 2015-12-30
JP2022084634A (ja) 2022-06-07
AU2018211351C1 (en) 2020-12-10
US20160184363A1 (en) 2016-06-30
AU2022206811A1 (en) 2022-08-18
US20230364150A1 (en) 2023-11-16
EP2972193A1 (en) 2016-01-20
US20200163999A1 (en) 2020-05-28
CN105209881B (zh) 2021-01-22
JP7417301B2 (ja) 2024-01-18
PT3677271T (pt) 2023-05-31
AU2022206811B2 (en) 2024-08-15
PT2972193T (pt) 2020-04-23
DK2972193T3 (da) 2020-03-23

Similar Documents

Publication Publication Date Title
DK2972193T3 (da) Fremgangsmåde til isolation og oprensning af mikrovesikler fra cellekultursupernatanter og biologiske fluider
DK2970872T3 (da) Mikroorganismer og fremgangsmåder til fremstilling af sialylerede og N-acetylglucosamin-holdige oligosaccharider
IL256525A (en) Taurine supplemented cell culture medium and methods of use
DK2855667T3 (da) Fremgangsmåder til manipulation af allogeniske og immunosuppressiv-resistante T-celler til immunterapi
DK2968415T3 (da) Cd123-specifik kimær antigenreceptor-omdirigerede t-celler og fremgangsmåder til anvendelse deraf
DK2919923T3 (da) Holder-sortiment og rengøringsapparater til rengøring af åndedrætsapparater
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2970890T3 (da) Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK3444342T3 (da) Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK2989470T3 (da) Indretning og fremgangsmåde til automatisk behandling af kulturplader til mikrobiologiske prøver
DK2553113T3 (da) FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK3399019T3 (da) Fremgangsmåder til bevaring af kulturs levedygtighed
DK3080353T3 (da) Fremgangsmåde til oprensning og isolering af lignin
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
DK3150710T3 (da) Fremgangsmåde til fremstilling af homoserin-lacton og organisk syre fra mikroorganisme-afledt o-acyl-homoserin
GB2525562B (en) Methods for purification of biological cells
DK3019452T3 (da) Fremgangsmåde for og installation af biologisk denitrifikation af spildevand
DK2864496T4 (da) Euglobulin-baseret fremgangsmåde til bestemmelse af den biologiske aktivitet af defibrotid
DK2882863T3 (da) System og fremgangsmåde til kvantitativ billeddannelse af mitokondriekompleks 1
DK3060659T3 (da) Alfa-amylaser fra exiguobacterium og fremgangsmåder til anvendelse deraf
DK3434306T3 (da) Indretning til adskillelse af gas og fluid